The EU AI ACT: Implications for the Medical Device Industry
The European Union’s recent strides in regulating artificial intelligence (AI) have garnered significant attention, particularly with the introduction of the EU AI Act. This landmark legislation aims to establish a comprehensive regulatory framework for AI systems across various sectors. Among those affected, the medical device industry finds itself at a crucial crossroads, as the implementation […]
ACLA’s Bold Move: Challenging FDA’s Final Rule on LDTs
In a groundbreaking legal maneuver, the American Clinical Laboratory Association (ACLA) has filed the first lawsuit in an attempt to block the implementation of the Food and Drug Administration’s (FDA) Final Rule on Laboratory Developed Tests (LDTs). The contentious Final Rule, which aims to regulate LDTs, has sparked heated debates within the healthcare and regulatory […]
MHRA Launches AI Airlock: Pioneering Innovation in Regulatory Oversight
The Medicines and Healthcare products Regulatory Agency (MHRA) has taken a bold step into the future of regulatory oversight with the launch of the AI Airlock initiative, a new regulatory sandbox designed to help understand risks related to AI as a Medical Device (AIaMD). This groundbreaking endeavor marks a significant leap forward in harnessing the […]
MHRA Proposes Stringent Requirements for High-Risk In Vitro Diagnostic Devices (IVDs)
In a bid to bolster patient safety and enhance regulatory oversight, the Medicines and Healthcare products Regulatory Agency (MHRA) has unveiled proposed requirements for high-risk in vitro diagnostic devices (IVDs) in the United Kingdom. The proposed measures, outlined in a recent consultation document, represent a significant step towards aligning UK regulatory standards with international best […]
Definitive MDSAP Program Update Webinar
Definitive mdsap program update webinar Simplify the intricacies of MDSAP with actionable insights and expert guidance. Watch this previously recorded webinar, “Definitive MDSAP Program Update: Strategies for Global Compliance & Market Success,” presented by MedTech Leading Voice. Here’s a glimpse at what to expect: Actionable tips to ensure a smooth MDSAP certification and audit process. […]
Accelerating Clinical Trials in the EU: Two Pilots Go Live
Clinical trials are the cornerstone of medical innovation, driving the development of new treatments and therapies that improve patient outcomes and advance healthcare. However, the traditional clinical trial process is often lengthy and complex, posing significant challenges for researchers, sponsors, and patients alike. The COVID-19 era brought a decrease in multi-state clinical trials applications in […]
Upcoming Regulation 2023/607 Transitional Provision Deadlines for MDR
On March 15, 2023, citing the impact of the COVID-19 pandemic, the lack of designated notified bodies and the associated over-capacities, and the imminent threat of significant shortages of necessary medical devices available on the market, the EU set forth Regulation 2023/607, amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for […]
Regulatory Science Tools Catalog
On May 13, 2024, FDA’s Office of Science and Engineering Laboratories (OSEL) launched an improved online Regulatory Science Tool (RST) Catalog to enhance search and browse capability as well as allow for long-term growth in published tools. The RST Catalog is now organized by research program and device type, cross referenced by both program and RST category, […]
FDA Issues Remanufacturing Guidance
On May 10, 2024, the FDA issued a guidance document on “Remanufacturing of Medical Devices.” Remanufacturing is the processing, conditioning, renovating, repackaging, restoring, or any other act done to a finished device that significantly changes the finished device’s performance or safety specifications, or intended use. The document is intended help clarify whether activities performed on […]
FDA Issues Final Rule on Laboratory Developed Tests
the FDA clarified that In vitro Diagnostic Devices (IVDs), including Laboratory Developed Tests (LDTs), are regulated as devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act), even when manufactured by laboratories. This move aims to enhance patient safety by phasing out enforcement discretion for most LDTs over four years, aligning requirements for IVDs regardless of where they are made.
